Independent
Tenure on this board
4.6 yrs
Meeting calendar
VOR · Special meeting · Monday, August 25, 2025
Vor Biopharma Inc
6 nominees · 3 ballot items.
Vor Biopharma Inc. seeks stockholder approval for three proposals: (1) the Issuance of warrants shares to be issued upon exercise of the Warrants under Nasdaq Listing Rule 5635(d) and related actions, (2) a board-authorized reverse stock split of the common stock in a ratio between 1-for-5 and 1-for-30, at the Board’s discretion, and (3) amendments to the Amended and Restated 2021 Equity Incentive Plan increasing the share reserve by 25,000,000 and extending the evergreen provision from 5% to 4% annually through 2035, among other changes.
Market cap
$997M
1Y TSR
+96.4%
Board grade
C
Record date
Jul 28, 2025
Filing
DEF 14A
Meeting concluded · Aug 25, 2025
Follow how the vote landed and what changed on Vor Biopharma Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Proposal No. 1 – The Issuance Proposal
ManagementBoard: FORTo approve, for purposes of Nasdaq Listing Rule 5635(d), the full issuance of shares of common stock issuable by the Company upon exercise of the Warrants (the “Warrants”). The Warrants would be exercisable only after stockholder approval and related amendments to the Certificate of Incorporation that increase authorized but unissued shares, as determined by the Board.
- 2
Proposal No. 2 – The Reverse Stock Split Proposal
ManagementBoard: FORTo approve a series of alternate amendments to the Certificate of Incorporation to effect a reverse stock split of all issued and outstanding shares at a ratio within the range of 1-for-5 to 1-for-30, inclusive, with the exact ratio and timing to be determined by the Board in its sole discretion.
- 3
Proposal No. 3 – The Equity Plan Proposal
ManagementBoard: FORTo approve the amendment and restatement of the Amended and Restated 2021 Equity Incentive Plan to (i) increase the number of common stock shares reserved for issuance by 25,000,000 and (ii) decrease the number of shares automatically added to the share reserve annually (the Evergreen Provision) from 5% to 4% of outstanding shares, through 2035, among other changes.
Director elections
Nominees on the ballot6
Independent
Tenure on this board
5.4 yrs
Also a director at
Upstream Bio Inc (UPB)
Independent
Tenure on this board
4.6 yrs
Also a director at
Dyne Therapeutics Inc (DYN)Crescent Biopharma Inc (CBIO)
Independent
Tenure on this board
6.4 yrs
Also a director at
Q32 Bio Inc (QTTB)
Independent
Tenure on this board
2.2 yrs
Not independent
Tenure on this board
4.5 yrs
Also a director at
Pepgen Inc (PEPG)Sionna Therapeutics Inc (SION)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | 10.5% | 5,673,078 | $96M |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 10.0% | 5,404,998 | $96M |
| 3 | FCPM III SERVICES B.V. | 7.6% | 4,117,354 | $73M |
| 4 | Venrock Adviser, LLC | 5.6% | 3,041,719 | $54M |
| 5 | Frazier Life Sciences Management, L.P. | 4.7% | 2,543,939 | $45M |
| 6 | Caligan Partners LPActivist | 3.6% | 1,925,066 | $34M |
| 7 | GREAT POINT PARTNERS LLC | 3.2% | 1,750,000 | $31M |
| 8 | Paradigm Biocapital Advisors LP | 3.2% | 1,750,000 | $31M |
| 9 | FMR LLC | 2.8% | 1,536,125 | $27M |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 2.6% | 1,433,280 | $26M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Vor Biopharma Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Esperion Therapeutics IncESPR
Special meeting·Jul 8, 2026·$814M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Xoma Royalty CorpXOMA
Annual meeting·Jul 13, 2026·$533M
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Reference
Frequently asked questions
- When is the Vor Biopharma Inc 2025 special meeting?
- Vor Biopharma Inc (VOR) holds its 2025 special shareholder meeting on Monday, August 25, 2025.
- What is the record date for the Vor Biopharma Inc 2025 meeting?
- The record date for the Vor Biopharma Inc 2025 meeting is Monday, July 28, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Vor Biopharma Inc's 2025 meeting?
- The board is presenting 6 director nominees at the Vor Biopharma Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Vor Biopharma Inc 2025 meeting?
- Shareholders will vote on 3 proposals at the Vor Biopharma Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.